TY - JOUR T1 - The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. JF - Clin Infect Dis. Y1 - 2015 A1 - Rein, DB. A1 - Wittenborn, JS. A1 - B.D. Smith A1 - et, al VL - 61 SP - 157-168 IS - 2 ER -